Keyphrases
Family Screening
100%
Melanoma
88%
Left Atrial Diameter
88%
Adjuvant Immunotherapy
88%
Anti-PD-1
88%
Electrical Investigations
88%
Hypertrophic Cardiomyopathy
88%
Risk Assessment
88%
Sudden Cardiac Death Prevention
88%
Left Atrial Volume
88%
Imaging Investigations
88%
Arrhythmogenic Right Ventricular Cardiomyopathy
88%
Idiopathic Dilated Cardiomyopathy
88%
Ipilimumab
71%
Adjuvant Therapy
35%
Melanoma-specific Survival
35%
Recurrence-free Survival
35%
Monotherapy
35%
Improved Outcomes
35%
Nivolumab
35%
Sudden Cardiac Death
26%
Baseline Screening
22%
Signal-averaged Electrocardiogram
22%
Holter Monitoring
22%
Non-invasive Assessment
22%
Incidence Rate
22%
Low Risk
22%
Cardiac Magnetic Resonance
22%
Stage III-IV
17%
Therapy Discontinuation
17%
Multivariable
17%
Patient Guidance
17%
Clinical Trials
17%
Performance Score
17%
National Cohort
17%
Survival Outcomes
17%
Treatment Decisions
17%
Metastatic Melanoma
17%
Melanoma Recurrence
17%
Population-based Study
17%
Real-life Data
17%
Randomized Controlled Trial
17%
Real Patients
17%
Patient Treatment
17%
Valuable Insight
17%
Positive Parameter
11%
Family Evaluation
11%
Genetic Baseline
11%
Inheritance Pattern
11%
Inherited Disease
11%
Pharmacology, Toxicology and Pharmaceutical Science
Immunotherapy
88%
Melanoma
88%
Heart Right Ventricle Dysplasia
88%
Ipilimumab
44%
Recurrent Disease
33%
Recurrence Free Survival
22%
Nivolumab
22%
Monotherapy
22%
Borderline State
22%
Randomized Controlled Trial
11%
Metastatic Melanoma
11%
Lactate Dehydrogenase
11%
Cardiovascular Symptom
11%
Clinical Trial
11%
Genetic Disorder
11%
Symptomatology
11%
Medicine and Dentistry
Sudden Cardiac Death
88%
Arrhythmogenic Right Ventricular Dysplasia
88%
Hypertrophic Cardiomyopathy
88%
Electrocardiogram
22%
Signal-Averaged Electrocardiogram
22%
Cardiology
22%
Cardiac Magnetic Resonance Imaging
22%
Diagnosis
22%
Holter Monitoring
22%
Cardiovascular Symptom
11%
Genetic Disorder
11%
Electrocardiography Monitoring
11%
Family History
11%
Symptomatology
11%
Diagnostic Imaging
11%
